Estrella Opens Fifth Site for Lymphoma T-Cell Therapy Study
Estrella Immunopharma has activated Intermountain Health LDS Hospital as the fifth clinical site for its Phase I/II STARLIGHT-1 study. The trial is testing EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with B-cell non-Hodgkin’s lymphoma. Estrella focuses on CD19- and CD22-targeted ARTEMIS T-cell therapies for cancer and autoimmune diseases.
Estrella Immunopharma has opened Intermountain Health LDS Hospital as the fifth location for STARLIGHT-1, a Phase I/II study. The trial is evaluating EB103, an ARTEMIS T-cell therapy that targets CD19, in people with B-cell non-Hodgkin’s lymphoma.
The company is a biopharma firm in clinical development. It is working on ARTEMIS T-cell therapies that target CD19 or CD22 for cancers and autoimmune diseases. Adding this site broadens where the investigational treatment can be studied.
For patients with B-cell non-Hodgkin’s lymphoma, another trial location may make participation easier to reach. Clinicians and families could gain more chances to discuss investigational options. If EB103 shows acceptable safety and benefit in STARLIGHT-1, the study may inform future treatment choices. It could also build experience with ARTEMIS T-cell approaches at the new site, though outcomes remain uncertain.